Millennium Management LLC Sells 266,668 Shares of Accuray Incorporated (NASDAQ:ARAY)

Millennium Management LLC lessened its stake in Accuray Incorporated (NASDAQ:ARAY) by 79.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,814 shares of the medical equipment provider’s stock after selling 266,668 shares during the period. Millennium Management LLC’s holdings in Accuray were worth $136,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in ARAY. Geode Capital Management LLC lifted its holdings in shares of Accuray by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 2,186,154 shares of the medical equipment provider’s stock worth $4,329,000 after acquiring an additional 6,758 shares during the last quarter. Northern Trust Corp increased its stake in Accuray by 0.9% in the fourth quarter. Northern Trust Corp now owns 809,665 shares of the medical equipment provider’s stock valued at $1,603,000 after acquiring an additional 7,399 shares during the last quarter. Ameriprise Financial Inc. purchased a new stake in Accuray during the fourth quarter valued at about $35,000. Renaissance Technologies LLC lifted its stake in Accuray by 6.8% during the fourth quarter. Renaissance Technologies LLC now owns 2,979,998 shares of the medical equipment provider’s stock worth $5,900,000 after purchasing an additional 189,414 shares during the last quarter. Finally, Prudential Financial Inc. bought a new stake in Accuray during the fourth quarter worth about $43,000. Institutional investors own 64.08% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Accuray from a “hold” rating to a “buy” rating in a report on Friday, May 30th.

Accuray Stock Performance

ARAY stock opened at $1.25 on Friday. The company has a market capitalization of $128.77 million, a PE ratio of -25.00 and a beta of 1.30. Accuray Incorporated has a one year low of $1.14 and a one year high of $2.95. The company’s 50 day moving average price is $1.51 and its two-hundred day moving average price is $1.86. The company has a debt-to-equity ratio of 3.51, a quick ratio of 0.88 and a current ratio of 1.62.

Accuray (NASDAQ:ARAY) last issued its earnings results on Wednesday, April 30th. The medical equipment provider reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.04. The company had revenue of $113.24 million for the quarter, compared to analysts’ expectations of $101.53 million. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. As a group, analysts predict that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.